col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world

236 Results       Page 1

Elsevier: The Lancet Microbe
  original article Date Title Authors   All Authors
1 [GO] 2024―Jun―13 Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study Sue Ann Costa Clemens, Brett Jepson, Qasim E Bhorat, Abdullahi Ahmad, Tauseefullah Akhund, Parvinder K Aley, et al. (+40)
2 [GO] 2024―Jun―06 SARS-CoV-2 detection and genomic surveillance: moving to ensure accessible tools in low-income and middle-income countries Severino Jefferson Ribeiro da Silva
3 [GO] 2024―May―27 Early trajectories of virological and immunological biomarkers and clinical outcomes in patients admitted to hospital for COVID-19: an international, prospective cohort study Tomas O Jensen, Thomas A Murray, Greg A Grandits, Mamta K Jain, Birgit Grund, Kathryn Shaw-Saliba, et al. (+1429)
4 [GO] 2024―May―15 SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial Brittany L Ober Shepherd, Paul T Scott, Jack N Hutter, Christine Lee, Melanie D McCauley, Ivelese Guzman, et al. (+78)
5 [GO] 2024―May―14 SARS-CoV-2 rapid antigen test sensitivity and viral load in newly symptomatic hospital employees in Berlin, Germany, December, 2020 to February, 2022: an observational study Leonie Meiners, Johanna Horn, Terry C Jones, Barbara Mühlemann, Marie Luisa Schmidt, Felix Walper, et al. (+7)
6 [GO] 2024―May―01 Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection study Susan Jackson, Julia L Marshall, Andrew Mawer, Raquel Lopez-Ramon, Stephanie A Harris, Iman Satti, et al. (+55)
7 [GO] 2024―Apr―24 Blood transcriptomic analyses reveal persistent SARS-CoV-2 RNA and candidate biomarkers in post-COVID-19 condition Soraya Maria Menezes, Marc Jamoulle, Maria Paula Carletto, Leen Moens, Isabelle Meyts, Piet Maes, Johan Van Weyenbergh
8 [GO] 2024―Apr―23 Assessing the entire landscape of antifungal immune response to COVID-19-associated pulmonary aspergillosis Florian Reizine, Jean-Marc Tadié, Murielle Grégoire, Karin Tarte, Jean-Pierre Gangneux
9 [GO] 2024―Apr―04 Viral clearance as a surrogate of clinical efficacy for COVID-19 therapies in outpatients: a systematic review and meta-analysis Karen M Elias, Shanchita R Khan, Eva Stadler, Timothy E Schlub, Deborah Cromer, Mark N Polizzotto, et al. (+4)
10 [GO] 2024―Mar―22 Effect of molnupiravir on SARS-CoV-2 evolution in immunocompromised patients: a retrospective observational study Nicholas M Fountain-Jones, Robert Vanhaeften, Jan Williamson, Janelle Maskell, I-Ly J Chua, Michael Charleston, Louise Cooley
11 [GO] 2024―Mar―11 Tracing the origin of SARS-CoV-2 omicron-like spike sequences detected in an urban sewershed: a targeted, longitudinal surveillance study of a cryptic wastewater lineage Martin M Shafer, Max J Bobholz, William C Vuyk, Devon A Gregory, Adelaide Roguet, Luis A Haddock Soto, et al. (+18)
12 [GO] 2024―Feb―14 Rapid evolution of pan-β-lactam resistance in Enterobacterales co-producing KPC and NDM: insights from global genomic analysis after the COVID-19 pandemic Fábio Parra Sellera, Nilton Lincopan, Danny Fuentes-Castillo, Eliana Guedes Stehling, João Pedro Rueda Furlan
13 [GO] 2024―Feb―12 Non-SARS-CoV-2 respiratory viral detection and whole genome sequencing from COVID-19 rapid antigen test devices: a laboratory evaluation study Michael A Moso, George Taiaroa, Eike Steinig, Madiyar Zhanduisenov, Grace Butel-Simoes, Ivana Savic, et al. (+16)
14 [GO] 2024―Feb―07 The omicron BA.2.86 subvariant as a new serotype of SARS-CoV-2 Pei Du, Chunli Wu, Shixiong Hu, Rui Fan, George Fu Gao, Qihui Wang
15 [GO] 2024―Jan―26 SARS-CoV-2 shedding and evolution in patients who were immunocompromised during the omicron period: a multicentre, prospective analysis Zoe Raglow, Diya Surie, James D Chappell, Yuwei Zhu, Emily T Martin, Jennie H Kwon, et al. (+20)
16 [GO] 2024―Jan―24 Lower respiratory tract single-cell RNA sequencing and neutrophil extracellular trap profiling of COVID-19-associated pulmonary aspergillosis: a single centre, retrospective, observational study Simon Feys, Sam Vanmassenhove, Sirima Kraisin, Karen Yu, Cato Jacobs, Bram Boeckx, et al. (+30)
17 [GO] 2024―Jan―21 RT-PCR genotyping assays to identify SARS-CoV-2 variants in England in 2021: a design and retrospective evaluation study Neil Bray, Will Sopwith, Matt Edmunds, Harper Vansteenhouse, Jelena D M Feenstra, Peter Jacobs, et al. (+12)
18 [GO] 2024―Jan―13 The importance of using WHO International Standards to harmonise SARS-CoV-2 serological assays Heidi Hempel, Mark Page, Troy Kemp, Amanda Semper, Tim Brooks, Ligia A Pinto
19 [GO] 2024―Jan―11 Characteristics of the SARS-CoV-2 omicron HK.3 variant harbouring the FLip substitution Yusuke Kosugi, Arnon Plianchaisuk, Olivia Putri, Keiya Uriu, Yu Kaku, Alfredo A Hinay, et al. (+73)
20 [GO] 2023―Dec―01 Bacterial nasopharyngeal colonisation in children in South Africa before and during the COVID-19 pandemic: an observational study Courtney P Olwagen, Sarah L Downs, Alane Izu, Lebohang Tharasimbi, Lara Van Der Merwe, Marta C Nunes, Shabir A Madhi
21 [GO] 2023―Dec―01 Durability and cross-reactive immune memory to SARS-CoV-2 in individuals 2 years after recovery from COVID-19: a longitudinal cohort study Li Guo, Qiao Zhang, Xiaoying Gu, Lili Ren, Tingxuan Huang, Yanan Li, et al. (+18)
22 [GO] 2023―Nov―23 Mycoplasma pneumoniae: delayed re-emergence after COVID-19 pandemic restrictions Patrick M Meyer Sauteur, Michael L Beeton, Sabine Pereyre, Cécile Bébéar, Marie Gardette, Nadège Hénin, et al. (+78)
23 [GO] 2023―Nov―16 Performance of SARS-CoV-2 nucleic acid amplification testing in Austria as measured by external quality assessment schemes during 3 years of the COVID-19 pandemic: an observational retrospective study Christoph Buchta, Stephan W Aberle, Franz Allerberger, Bernhard Benka, Irene Görzer, Andrea Griesmacher, et al. (+8)
24 [GO] 2023―Nov―02 Determinants of passive antibody efficacy in SARS-CoV-2 infection: a systematic review and meta-analysis Eva Stadler, Khai Li Chai, Timothy E Schlub, Deborah Cromer, Shanchita R Khan, Mark N Polizzotto, et al. (+10)
25 [GO] 2023―Oct―30 SARS-CoV-2 neutralising antibody response to bivalent booster after omicron infection David N Springer, Iris Medits, Lukas Weseslindtner, Karin Stiasny, Judith H Aberle
26 [GO] 2023―Oct―13 Accuracy of package inserts of SARS-CoV-2 rapid antigen tests: a secondary analysis of manufacturer versus systematic review data Jacob Bigio, Emily L-H MacLean, Rishav Das, Giorgia Sulis, Mikashmi Kohli, Sarah Berhane, et al. (+5)
27 [GO] 2023―Oct―13 New licences for the COVID-19 Technology Access Pool Priya Venkatesan
28 [GO] 2023―Sep―29 Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland Maheshi N Ramasamy, Elizabeth J Kelly, Seth Seegobin, Paul I Dargan, Ruth Payne, Vincenzo Libri, et al. (+47)
29 [GO] 2023―Sep―28 From HPV to COVID-19 and beyond: leveraging the power of serology and standards Heidi A Hempel, Troy J Kemp, Nancy Roche, Ligia A Pinto
30 [GO] 2023―Sep―22 COVID-19 boosters: If everyone is at risk, no one is at risk The Lancet Microbe
31 [GO] 2023―Aug―30 Viral kinetics of SARS-CoV-2 following onset of COVID-19 in symptomatic patients infected with the ancestral strain and omicron BA.2 in Hong Kong: a retrospective observational study Yun Lin, Peng Wu, Tim K Tsang, Jessica Y Wong, Eric H Y Lau, Bingyi Yang, et al. (+2)
32 [GO] 2023―Aug―25 Towards the development of a SARS-CoV-2 variant risk assessment tool: expert consultation on the assessment of scientific evidence on emerging variants Nathalie Worp, Lorenzo Subissi, Mark D Perkins, Maria D Van Kerkhove, Anurag Agrawal, Meera Chand, et al. (+3)
33 [GO] 2023―Aug―25 Is it possible to generalise superspreading individuals or events of SARS-CoV-2? Sunil Shrestha, Yudai Kaneda, Kenzo Takahashi, Akihiko Ozaki, Siew Hua Gan
34 [GO] 2023―Aug―25 Is it possible to generalise superspreading individuals or events of SARS-CoV-2? - Authors' reply Jie Zhou, Anika Singanayagam, Wendy S Barclay
35 [GO] 2023―Aug―07 Dynamics of inflammatory responses after SARS-CoV-2 infection by vaccination status in the USA: a prospective cohort study Xianming Zhu, Kelly A Gebo, Alison G Abraham, Feben Habtehyimer, Eshan U Patel, Oliver Laeyendecker, et al. (+42)
36 [GO] 2023―Jul―14 Viral and antibody dynamics of acute infection with SARS-CoV-2 omicron variant (B.1.529): a prospective cohort study from Shenzhen, China Yang Yang, Liping Guo, Jing Yuan, Zhixiang Xu, Yuchen Gu, Jiaqi Zhang, et al. (+4)
37 [GO] 2023―Jun―26 Viral persistence in children infected with SARS-CoV-2: current evidence and future research strategies Danilo Buonsenso, Laura Martino, Rosa Morello, Francesco Mariani, Kelly Fearnley, Piero Valentini
38 [GO] 2023―Jun―22 Immune response after two doses of the BNT162b2 COVID-19 vaccine and risk of SARS-CoV-2 breakthrough infection in Tyrol, Austria: an open-label, observational phase 4 trial Lisa Seekircher, Zoltán Bánki, Janine Kimpel, Annika Rössler, Helena Schäfer, Barbara Falkensammer, et al. (+40)
39 [GO] 2023―Jun―10 Viral emissions into the air and environment after SARS-CoV-2 human challenge: a phase 1, open label, first-in-human study Jie Zhou, Anika Singanayagam, Niluka Goonawardane, Maya Moshe, Fiachra P Sweeney, Ksenia Sukhova, et al. (+8)
40 [GO] 2023―May―23 The SARS-CoV-2 furin cleavage site: natural selection or smoking gun? Bailey Lubinski, Gary R Whittaker
41 [GO] 2023―May―01 Bivalent COVID-19 booster vaccines and the absence of BA.5-specific antibodies Juan Manuel Carreño, Gagandeep Singh, Viviana Simon, Florian Krammer
42 [GO] 2023―Apr―25 Effect of viral storm in patients admitted to intensive care units with severe COVID-19 in Spain: a multicentre, prospective, cohort study Jesús F Bermejo-Martin, Nadia García-Mateo, Anna Motos, Salvador Resino, Luis Tamayo, Pablo Ryan Murua, et al. (+74)
43 [GO] 2023―Apr―25 First shared SARS-CoV-2 genome: GISAID vs Talha Burki
44 [GO] 2023―Apr―24 Replicative capacity of SARS-CoV-2 omicron variants BA.5 and BQ.1.1 at elevated temperatures Yukiko Muramoto, Senye Takahashi, Peter J Halfmann, Shimpei Gotoh, Takeshi Noda, Yoshihiro Kawaoka
45 [GO] 2023―Apr―20 Mucosal immune responses following a fourth SARS-CoV-2 vaccine dose Oscar Bladh, Ulrika Marking, Sebastian Havervall, Nina Greilert Norin, Katherina Aguilera, Sophia Hober, et al. (+6)
46 [GO] 2023―Apr―18 SARS-CoV-2 incubation period across variants of concern, individual factors, and circumstances of infection in France: a case series analysis from the ComCor study Simon Galmiche, Thomas Cortier, Tiffany Charmet, Laura Schaeffer, Olivia Chény, Cassandre von Platen, et al. (+8)
47 [GO] 2023―Apr―15 Integrating tuberculosis and COVID-19 molecular testing in Lima, Peru: a cross-sectional, diagnostic accuracy study Emily Lai-Ho MacLean, Luz Villa-Castillo, Patricia Espinoza-Lopez, Tatiana Caceres, Giorgia Sulis, Mikashmi Kohli, et al. (+2)
48 [GO] 2023―Apr―14 Hybrid immunity against reinfection with SARS-CoV-2 following a previous SARS-CoV-2 infection and single dose of the BNT162b2 vaccine in children and adolescents: a target trial emulation Sivan Gazit, Yaki Saciuk, Galit Perez, Asaf Peretz, Amir Ben-Tov, Elizabeth A Stuart, Tal Patalon
49 [GO] 2023―Apr―06 Association of IFNAR1 and IFNAR2 with COVID-19 severity Melyssa Yaugel-Novoa, Thomas Bourlet, Stéphanie Longet, Elisabeth Botehlo-Nevers, Stéphane Paul
50 [GO] 2023―Apr―06 Assessing the potential for fomite transmission of SARS-CoV-2 Kirsty R Short, Benjamin J Cowling
51 [GO] 2023―Apr―06 Risk factors and vectors for SARS-CoV-2 household transmission: a prospective, longitudinal cohort study Nieves Derqui, Aleksandra Koycheva, Jie Zhou, Timesh D Pillay, Michael A Crone, Seran Hakki, et al. (+48)
52 [GO] 2023―Apr―03 Real-time sewage surveillance for SARS-CoV-2 in Dhaka, Bangladesh versus clinical COVID-19 surveillance: a longitudinal environmental surveillance study (December, 2019-December, 2021) Elizabeth T Rogawski McQuade, Isobel M Blake, Stephanie A Brennhofer, Md Ohedul Islam, Syed Shahnewaj Siraj Sony, Tonima Rahman, et al. (+15)
53 [GO] 2023―Mar―24 MPXV and SARS-CoV-2 in the air of nightclubs in Spain África Sanchiz, Rocío Martín, Margarita Del Val, Alfredo Corell, Antonio Alcamí
54 [GO] 2023―Mar―24 Bivalent mRNA vaccine-elicited SARS-CoV-2 specific T cells recognise the omicron XBB sublineage Caroline C Traut, Joel N Blankson
55 [GO] 2023―Mar―22 Wastewater concentrations of human influenza, metapneumovirus, parainfluenza, respiratory syncytial virus, rhinovirus, and seasonal coronavirus nucleic-acids during the COVID-19 pandemic: a surveillance study Alexandria B Boehm, Bridgette Hughes, Dorothea Duong, Vikram Chan-Herur, Anna Buchman, Marlene K Wolfe, Bradley J White
56 [GO] 2023―Mar―21 Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): a prospective cohort study Gili Regev-Yochay, Yaniv Lustig, Gili Joseph, Mayan Gilboa, Noam Barda, Ilana Gens, et al. (+17)
57 [GO] 2023―Mar―21 Searching for SARS-CoV-2 origins: confidence versus evidence The Lancet Microbe
58 [GO] 2023―Mar―16 Advances in developing ACE2 derivatives against SARS-CoV-2 Haoran Zhang, Panjing Lv, Jingrui Jiang, Yahui Liu, Ruixi Yan, Sainan Shu, et al. (+5)
59 [GO] 2023―Mar―15 Appropriate antimicrobial use during the COVID-19 pandemic: not cause for complacency Nikolaos Spernovasilis, Aris P Agouridis, Constantinos Tsioutis
60 [GO] 2023―Feb―28 Efficacy of SARS-CoV-2 vaccines and the dose-response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled trials Zhi-Rong Yang, Yi-Wen Jiang, Fu-Xiao Li, Di Liu, Teng-Fei Lin, Zi-Yi Zhao, et al. (+9)
61 [GO] 2023―Feb―15 Peptide microarray IgM and IgG screening of pre-SARS-CoV-2 human serum samples from Zimbabwe for reactivity with peptides from all seven human coronaviruses: a cross-sectional study Jordan Ashworth, Dayna Mathie, Fiona Scott, Yuvaraj Mahendran, Mark Woolhouse, Oda Stoevesandt, et al. (+2)
62 [GO] 2023―Feb―10 The emerging antimicrobial resistance crisis during the COVID-19 surge in China Zhicheng Wang, Mengke Yu, Leesa Lin
63 [GO] 2023―Feb―03 Ignoring SARS-CoV-2 testing performance during COVID-19 Christoph Buchta, Heinz Zeichhardt, Andrea Griesmacher, Ingo Schellenberg, Martin Kammel
64 [GO] 2023―Feb―01 Antimicrobial resistance in patients with COVID-19: a systematic review and meta-analysis Bradley J Langford, Miranda So, Marina Simeonova, Valerie Leung, Jennifer Lo, Tiffany Kan, et al. (+10)
65 [GO] 2023―Feb―01 The influenza imperative: we must prepare now for seasonal and pandemic influenza Victor Dzau, Prashant Yadav
66 [GO] 2023―Jan―28 COVID-19 lateral flow IgG seropositivity and serum neutralising antibody responses after primary and booster vaccinations in Chile: a cross-sectional study Denis Sauré, Miguel O'Ryan, Juan Pablo Torres, Marcela Zuñiga, Ricardo Soto-Rifo, Fernando Valiente-Echeverría, et al. (+8)
67 [GO] 2023―Jan―18 First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2 Merel J Smit, Adam F Sander, Maud B P A Ariaans, Cyrielle Fougeroux, Constanze Heinzel, Rolf Fendel, et al. (+60)
68 [GO] 2023―Jan―16 Antigenic mapping of emerging SARS-CoV-2 omicron variants BM.1.1.1, BQ.1.1, and XBB.1 Anna Z Mykytyn, Miruna E Rosu, Adinda Kok, Melanie Rissmann, Geert van Amerongen, Corine Geurtsvankessel, et al. (+7)
69 [GO] 2022―Dec―21 Ecology of SARS-CoV-2 in the post-pandemic era Yafei Meng, David M Irwin, Yongyi Shen
70 [GO] 2022―Nov―12 Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study Hiam Chemaitelly, Houssein H Ayoub, Sawsan AlMukdad, Peter Coyle, Patrick Tang, Hadi M Yassine, et al. (+18)
71 [GO] 2022―Nov―01 Vaccination and protective immunity to SARS-CoV-2 omicron variants in people with immunodeficiencies Angalee Nadesalingam, Diego Cantoni, Ernest T Aguinam, Andrew CY Chan, Minna Paloniemi, Luis Ohlendorf, et al. (+9)
72 [GO] 2022―Aug―31 Methods for early characterisation of the severity and dynamics of SARS-CoV-2 variants: a population-based time series analysis in South Africa Emily Reichert, Beau Schaeffer, Shae Gantt, Eva Rumpler, Nevashan Govender, Richard Welch, et al. (+10)
73 [GO] 2022―Aug―24 Transmission of SARS-CoV-2 by children to contacts in schools and households: a prospective cohort and environmental sampling study in London Rebecca Cordery, Lucy Reeves, Jie Zhou, Aileen Rowan, Patricia Watber, Carolina Rosadas, et al. (+18)
74 [GO] 2022―Aug―11 Mycoplasma pneumoniae beyond the COVID-19 pandemic: where is it? Patrick M Meyer Sauteur, Victoria J Chalker, Christoph Berger, Ran Nir-Paz, Michael L Beeton, Sabine Pereyre, et al. (+54)
75 [GO] 2022―Aug―10 Comparative neutralisation profile of SARS-CoV-2 omicron subvariants BA.2.75 and BA.5 Chee-Wah Tan, Beng-Lee Lim, Barnaby E Young, Aileen Ying-Yan Yeoh, Chee-Fu Yung, Wee-Chee Yap, et al. (+5)
76 [GO] 2022―Aug―10 The pandemic legacy of antimicrobial resistance in the USA Jay Patel, Devi Sridhar
77 [GO] 2022―Aug―03 Effect of pneumococcal conjugate vaccines and SARS-CoV-2 on antimicrobial resistance and the emergence of Streptococcus pneumoniae serotypes with reduced susceptibility in Spain, 2004-20: a national surveillance study Julio Sempere, Mirella Llamosí, Beatriz López Ruiz, Idoia del Río, Covadonga Pérez-García, Darío Lago, et al. (+5)
78 [GO] 2022―Jul―22 Spillover infection of common animal coronaviruses to humans Shao-Lun Zhai, Ming-Fei Sun, Jian-Feng Zhang, Chunfu Zheng, Ming Liao
79 [GO] 2022―Jun―29 Searching for SARS-CoV-2 origins: the saga continues The Lancet Microbe
80 [GO] 2022―May―31 Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine Guangting Zeng
81 [GO] 2022―May―27 Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: a serological analysis Frauke Muecksch, Helen Wise, Kate Templeton, Becky Batchelor, Maria Squires, Kirsty McCance, et al. (+13)
82 [GO] 2022―May―27 Sotrovimab drives SARS-CoV-2 omicron variant evolution in immunocompromised patients Grégory Destras, Antonin Bal, Bruno Simon, Bruno Lina, Laurence Josset
83 [GO] 2022―May―24 Co-infection with SARS-CoV-2 omicron BA.1 and BA.2 subvariants in a non-vaccinated woman Maria Linda Vatteroni, Anna-Lisa Capria, Pietro Giorgio Spezia, Susi Frateschi, Mauro Pistello
84 [GO] 2022―Apr―21 Delays in the arrival of the waves of COVID-19: a comparison between Gabon and the African continent Haruka Abe, Yuri Ushijima, Rodrigue Bikangui, Georgelin Nguema Ondo, Bertrand Lell, Ayola A Adegnika, Jiro Yasuda
85 [GO] 2022―Mar―28 Serum neutralisation of the SARS-CoV-2 omicron sublineage BA.2 Lin-Lei Chen, Allen Wing-Ho Chu, Ricky Rui-Qi Zhang, Ivan Fan-Ngai Hung, Kelvin Kai-Wang To
86 [GO] 2022―Mar―24 SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study Li Guo, Geng Wang, Yeming Wang, Qiao Zhang, Lili Ren, Xiaoying Gu, et al. (+14)
87 [GO] 2022―Mar―15 Monitoring and managing SARS-CoV-2 evolution in immunocompromised populations Pengfei Li, Annemarie C de Vries, Nassim Kamar, Maikel P Peppelenbosch, Qiuwei Pan
88 [GO] 2022―Mar―09 Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial Flavia Chiuppesi, John A Zaia, Paul H Frankel, Rodica Stan, Jennifer Drake, Brenda Williams, et al. (+29)
89 [GO] 2022―Mar―03 Global polio eradication set back by COVID-19 pandemic Priya Venkatesan
90 [GO] 2022―Mar―03 An ounce of pandemic prevention is worth a pound of cure The Lancet Microbe
91 [GO] 2022―Feb―09 Safety and immunogenicity of two recombinant DNA COVID-19 vaccines containing the coding regions of the spike or spike and nucleocapsid proteins: an interim analysis of two open-label, non-randomised, phase 1 trials in healthy adults Jin Young Ahn, Jeongsoo Lee, You Suk Suh, Young Goo Song, Yoon-Jeong Choi, Kyoung Hwa Lee, et al. (+12)
92 [GO] 2022―Feb―09 Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study Burc Barin, Ulus Kasap, Ferda Selçuk, Ender Volkan, Özge Uluçkan
93 [GO] 2022―Feb―07 Post-recovery enhancement of anti-variant neutralisation after severe COVID-19 Yingying Lu, Yufang Zhu, Miao Cui, Zhengjiang Cheng, Peng Hong
94 [GO] 2022―Jan―25 The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries Martin Hoenigl, Danila Seidel, Agostinho Carvalho, Shivaprakash M Rudramurthy, Amir Arastehfar, Jean-Pierre Gangneux, et al. (+11)
95 [GO] 2022―Jan―25 The importance of external quality assessment data in evaluating SARS-CoV-2 virus genome detection assays Christoph Buchta, Mathias M Müller, Andrea Griesmacher
96 [GO] 2022―Jan―25 The importance of external quality assessment data in evaluating SARS-CoV-2 virus genome detection assays - Authors‘ reply Wing Ying Au, Peter Pak Hang Cheung
97 [GO] 2022―Jan―24 Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial Gui-Ling Chen, Xiao-Feng Li, Xia-Hong Dai, Nan Li, Meng-Li Cheng, Zhen Huang, et al. (+25)
98 [GO] 2022―Jan―07 Enterovirus D68: a test case for the use of immunological surveillance to develop tools to mitigate the pandemic potential of emerging pathogens Hai Nguyen-Tran, Sang Woo Park, Kevin Messacar, Samuel R Dominguez, Matthew R Vogt, Sallie Permar, et al. (+7)
99 [GO] 2021―Dec―24 A protein subunit vaccine booster following two doses oZactivated SARS-CoV-2 vaccine provides high neutralisation of SARS-CoV-2 and its variants in mice Rong Zhang, Dedong Li, Kun Xu, Chenxi Yang, Tingrong Luo, Xin Zhao, George F Gao
100 [GO] 2021―Dec―24 Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants Scott J C Pallett, Joseph Heskin, Elisabetta Groppelli, Andrea Mazzella, Luke S P Moore
101 [GO] 2021―Dec―03 Severe breakthrough COVID-19 cases in the SARS-CoV-2 delta (B.1.617.2) variant era Stephen Y Wang, Prerak V Juthani, Kelly A Borges, Marcus K Shallow, Akash Gupta, Christina Price, et al. (+2)
102 [GO] 2021―Dec―03 WHO international standard for SARS-CoV-2 antibodies to determine markers of protection Feng Zhu, Thomas Althaus, Chee Wah Tan, Alizée Costantini, Wan Ni Chia, Nguyen Van Vinh Chau, et al. (+5)
103 [GO] 2021―Nov―25 SARS-CoV-2 antigen-detecting rapid tests for the delta variant Meriem Bekliz, Kenneth Adea, Manel Essaidi-Laziosi, Jilian A Sacks, Camille Escadafal, Laurent Kaiser, Isabella Eckerle
104 [GO] 2021―Nov―16 Access and benefit-sharing by the European Virus Archive in response to COVID-19 Scarlett Sett, Carolina dos Santos Ribeiro, Christine Prat, George Haringhuizen, Amber Hartman Scholz, Tatjana Avšič, et al. (+22)
105 [GO] 2021―Nov―15 Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis Deborah Cromer, Megan Steain, Arnold Reynaldi, Timothy E Schlub, Adam K Wheatley, Jennifer A Juno, et al. (+4)
106 [GO] 2021―Nov―09 One world, one health, one virology of the mysterious labyrinth of coronaviruses: the canine coronavirus affair Annamaria Pratelli, Alessio Buonavoglia, Gianvito Lanave, Maria Tempesta, Michele Camero, Vito Martella, Nicola Decaro
107 [GO] 2021―Nov―09 T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study Adrienn Angyal, Stephanie Longet, Shona C Moore, Rebecca P Payne, Adam Harding, Tom Tipton, et al. (+173)
108 [GO] 2021―Nov―03 Closing Africa's wide COVID-19 testing and vaccination gaps Paul Adepoju
109 [GO] 2021―Oct―27 WHO International Standard for evaluation of the antibody response to COVID-19 vaccines: call for urgent action by the scientific community Ivana Knezevic, Giada Mattiuzzo, Mark Page, Philip Minor, Elwyn Griffiths, Micha Nuebling, Vasee Moorthy
110 [GO] 2021―Oct―25 Current malaria infection, previous malaria exposure, and clinical profiles and outcomes of COVID-19 in a setting of high malaria transmission: an exploratory cohort study in Uganda Jane Achan, Asadu Serwanga, Humphrey Wanzira, Tonny Kyagulanyi, Anthony Nuwa, Godfrey Magumba, et al. (+11)
111 [GO] 2021―Oct―13 Diagnostic performances of common nucleic acid tests for SARS-CoV-2 in hospitals and clinics: a systematic review and meta-analysis Wing Ying Au, Peter Pak Hang Cheung
112 [GO] 2021―Oct―02 The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study Jeffrey P Townsend, Hayley B Hassler, Zheng Wang, Sayaka Miura, Jaiveer Singh, Sudhir Kumar, et al. (+3)
113 [GO] 2021―Sep―30 The role of viral genomics in understanding COVID-19 outbreaks in long-term care facilities Dinesh Aggarwal, Richard Myers, William L Hamilton, Tehmina Bharucha, Niamh M Tumelty, Colin S Brown, et al. (+14)
114 [GO] 2021―Sep―29 Is the tuberculosis response another casualty of COVID-19? The Lancet Microbe
115 [GO] 2021―Aug―28 Estimating clinical SARS-CoV-2 infectiousness in Vero E6 and primary airway epithelial cells Manel Essaidi-Laziosi, Francisco Javier Perez Rodriguez, Nicolas Hulo, Frederique Jacquerioz, Laurent Kaiser, Isabella Eckerle
116 [GO] 2021―Aug―26 COVID-19: stewardship of diagnostic tests for bacterial co-infection Tom G S Williams, Luke B Snell, Jonathan D Edgeworth, Geraldine A O'Hara
117 [GO] 2021―Aug―20 Neutralisation of ZF2001-elicited antisera to SARS-CoV-2 variants Xin Zhao, Anqi Zheng, Dedong Li, Rong Zhang, Huan Sun, Qihui Wang, et al. (+3)
118 [GO] 2021―Aug―16 Discovery and validation of a three-gene signature to distinguish COVID-19 and other viral infections in emergency infectious disease presentations: a case-control and observational cohort study Ho Kwong Li, Myrsini Kaforou, Jesus Rodriguez-Manzano, Samuel Channon-Wells, Ahmad Moniri, Dominic Habgood-Coote, et al. (+18)
119 [GO] 2021―Aug―06 Could Egyptian mummies tell us more about the history of coronaviruses? AbdulRahman A Saied, Jaffer Shah, Asmaa A Metwally, Hani Aiash
120 [GO] 2021―Aug―06 SARS-CoV-2 spike and its adaptable furin cleavage site Gary R Whittaker
121 [GO] 2021―Aug―03 UK Government's COVID-19 gamble The Lancet Microbe
122 [GO] 2021―Aug―03 Preventing zoonotic pandemics: are we there yet? Karl Gruber
123 [GO] 2021―Jul―28 Bamlanivimab as monotherapy in two immunocompromised patients with COVID-19 Grégory Destras, Souad Assaad, Antonin Bal, Maude Bouscambert-Duchamp, Virginie Avrillon, Bruno Simon, et al. (+5)
124 [GO] 2021―Jul―27 Genomic surveillance to combat COVID-19: challenges and opportunities Janet D Robishaw, Scott M Alter, Joshua J Solano, Richard D Shih, David L DeMets, Dennis G Maki, Charles H Hennekens
125 [GO] 2021―Jul―16 Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19 Wey Wen Lim, Loretta Mak, Gabriel M Leung, Benjamin J Cowling, Malik Peiris
126 [GO] 2021―Jul―08 Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study William M Souza, Mariene R Amorim, Renata Sesti-Costa, Lais D Coimbra, Natalia S Brunetti, Daniel A Toledo-Teixeira, et al. (+50)
127 [GO] 2021―Jul―06 Blood transcriptional biomarkers of acute viral infection for detection of pre-symptomatic SARS-CoV-2 infection: a nested, case-control diagnostic accuracy study Rishi K Gupta, Joshua Rosenheim, Lucy C Bell, Aneesh Chandran, Jose A Guerra-Assuncao, Gabriele Pollara, et al. (+128)
128 [GO] 2021―Jul―01 Rising antimicrobial resistance: an evolving epidemic in a pandemic Abi Manesh, George M Varghese
129 [GO] 2021―Jun―30 Comparative performance of SARS-CoV-2 lateral flow antigen tests and association with detection of infectious virus in clinical specimens: a single-centre laboratory evaluation study Suzanne Pickering, Rahul Batra, Blair Merrick, Luke B Snell, Gaia Nebbia, Sam Douthwaite, et al. (+15)
130 [GO] 2021―Jun―29 COVID-19 vaccination among Roma populations in Europe Ed Holt
131 [GO] 2021―Jun―29 WHO-Germany collaboration for pandemic intelligence research Vijay Shankar Balakrishnan
132 [GO] 2021―Jun―29 G7 leaders commit to greater pandemic preparedness (again) The Lancet Microbe
133 [GO] 2021―Jun―29 SARS-CoV-2 rapid diagnostic tests for emerging variants Meriem Bekliz, Kenneth Adea, Manel Essaidi-Laziosi, Jilian A Sacks, Camille Escadafal, Laurent Kaiser, Isabella Eckerle
134 [GO] 2021―Jun―28 Paucity and discordance of neutralising antibody responses to SARS-CoV-2 VOCs in vaccinated immunodeficient patients and health-care workers in the UK Angalee Nadesalingam, Diego Cantoni, David A Wells, Ernest T Aguinam, Matteo Ferrari, Peter Smith, et al. (+10)
135 [GO] 2021―Jun―23 Invasive mould disease in fatal COVID-19: a systematic review of autopsies Brittany E Kula, Cornelius J Clancy, M Hong Nguyen, Ilan S Schwartz
136 [GO] 2021―Jun―18 Beyond vaccine hesitancy: time for Africa to expand vaccine manufacturing capacity amidst growing COVID-19 vaccine nationalism Akaninyene Otu, Egbe Osifo-Dawodu, Phionah Atuhebwe, Emmanuel Agogo, Bassey Ebenso
137 [GO] 2021―Jun―08 SARS-CoV-2 emerging variants in Africa: view from Gabon Samira Zoa-Assoumou, Bénédicte Ndeboko, Gédéon Prince Manouana, Rotimi Myrabelle Avome Houechenou, Rodrigue Bikangui, Amandine Mveang-Nzoghe, et al. (+9)
138 [GO] 2021―Jun―02 India grapples with second wave of COVID-19 Udani Samarasekera
139 [GO] 2021―Jun―02 Combining immunomodulators and antivirals for COVID-19 Luke Y C Chen, Tien T T Quach
140 [GO] 2021―Jun―02 Combining immunomodulators and antivirals for COVID-19 - Authors' reply Raquel Almansa, Ana P Tedim, Amanda de la Fuente, Jose María Eiros, David J Kelvin, Antoni Torres, Jesus F Bermejo-Martin
141 [GO] 2021―Jun―02 Convalescent plasma transfusion for pregnant patients with COVID-19 Antonio Mastroianni, Sonia Greco, Maria Vittoria Mauro, Luciana Chidichimo, Valeria Vangeli
142 [GO] 2021―Jun―02 Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study Clark D Russell, Cameron J Fairfield, Thomas M Drake, Lance Turtle, R Andrew Seaton, Dan G Wootton, et al. (+366)
143 [GO] 2021―May―19 A novel strategy for SARS-CoV-2 mass screening with quantitative antigen testing of saliva: a diagnostic accuracy study Isao Yokota, Peter Y Shane, Kazufumi Okada, Yoko Unoki, Yichi Yang, Sumio Iwasaki, et al. (+3)
144 [GO] 2021―May―14 COVID-19 vaccines: effectiveness and number needed to treat - Authors' reply Piero Olliaro, Els Torreele, Michel Vaillant
145 [GO] 2021―May―14 COVID-19 vaccines: effectiveness and number needed to treat Luis C L Correia, Denise Matias
146 [GO] 2021―May―12 Rapid tests for quantification of infectiousness are urgently required in patients with COVID-19 Daniel Pan, Shirley Sze, Shalin Abraham, Caroline M Williams, Julian W Tang, Mike R Barer, Manish Pareek
147 [GO] 2021―May―04 No end in sight for the Brazilian COVID-19 crisis Talha Burki
148 [GO] 2021―Apr―21 Targeting hyperinflammation in infection: can we harness the COVID-19 therapeutics momentum to end the dengue drugs drought? Angela McBride, Puja Mehta, Laura Rivino, Athimalaipet V Ramanan, Sophie Yacoub
149 [GO] 2021―Apr―21 COVID-19 vaccine efficacy and effectiveness-the elephant (not) in the room Piero Olliaro, Els Torreele, Michel Vaillant
150 [GO] 2021―Apr―16 Mounting evidence of impaired viral control in severe COVID-19 Jesus F Bermejo-Martin, Raquel Almansa, Ana P Tedim, Amanda de la Fuente, Jose María Eiros, Antoni Torres, David J Kelvin
151 [GO] 2021―Apr―15 Serum sample neutralisation of BBIBP-CorV and ZF2001 vaccines to SARS-CoV-2 501Y.V2 Baoying Huang, Lianpan Dai, Hui Wang, Zhongyu Hu, Xiaoming Yang, Wenjie Tan, George F Gao
152 [GO] 2021―Apr―07 Comparison of seven commercial SARS-CoV-2 rapid point-of-care antigen tests: a single-centre laboratory evaluation study Victor M Corman, Verena Claudia Haage, Tobias Bleicker, Marie Luisa Schmidt, Barbara Mühlemann, Marta Zuchowski, et al. (+7)
153 [GO] 2021―Apr―07 SARS-CoV-2 spike E484K mutation reduces antibody neutralisation Sonia Jangra, Chengjin Ye, Raveen Rathnasinghe, Daniel Stadlbauer, Florian Krammer, Viviana Simon, et al. (+24)
154 [GO] 2021―Apr―01 A method for detection of SARS-CoV-2 RNA in healthy human stool: a validation study Michael P Coryell, Mikhail Iakiviak, Nicole Pereira, Pallavi P Murugkar, Jason Rippe, David B Williams, et al. (+10)
155 [GO] 2021―Mar―31 Potential benefit of convalescent plasma transfusions in immunocompromised patients with COVID-19 Roman N Rodionov, Anne Biener, Peter Spieth, Martin Achleitner, Kristina Hölig, Martin Aringer, et al. (+6)
156 [GO] 2021―Mar―31 Endogenous IFNβ expression predicts outcome in critical patients with COVID-19 Soraya Maria Menezes, Marcos Braz, Veronica Llorens-Rico, Joost Wauters, Johan Van Weyenbergh
157 [GO] 2021―Mar―31 Challenges of SARS-CoV-2 genomic surveillance in Africa Paul Adepoju
158 [GO] 2021―Mar―23 Convalescent plasma from people vaccinated after COVID-19 infection Kamal Abu Jabal, Karine Beiruti Wiegler, Michael Edelstein
159 [GO] 2021―Mar―23 Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study Wan Ni Chia, Feng Zhu, Sean Wei Xiang Ong, Barnaby Edward Young, Siew-Wai Fong, Nina Le Bert, et al. (+16)
160 [GO] 2021―Mar―21 Learning from COVID-19 to reimagine tuberculosis diagnosis Morten Ruhwald, Sergio Carmona, Madhukar Pai
161 [GO] 2021―Mar―14 Perfect as the enemy of good: tracing transmissions with low-sensitivity tests to mitigate SARS-CoV-2 outbreaks Lee Kennedy-Shaffer, Michael Baym, William P Hanage
162 [GO] 2021―Mar―12 Surveillance of SARS-CoV-2 in Zimbabwe shows dominance of variants of concern Tapfumanei Mashe, Faustinos Tatenda Takawira, Hlanai Gumbo, Agnes Juru, Charles Nyagupe, Kenneth K Maeka, et al. (+7)
163 [GO] 2021―Mar―07 Interferon antagonism by SARS-CoV-2: a functional study using reverse genetics Simon Schroeder, Fabian Pott, Daniela Niemeyer, Talitha Veith, Anja Richter, Doreen Muth, et al. (+3)
164 [GO] 2021―Mar―03 Revisiting the initial COVID-19 pandemic projections Adam T Biggs, Lanny F Littlejohn
165 [GO] 2021―Feb―24 SARS-CoV-2: eye protection might be the missing key Minas Theodore Coroneo, Peter John Collignon
166 [GO] 2021―Feb―24 COVID-19 drug practices risk antimicrobial resistance evolution Ebrahim Afshinnekoo, Chandrima Bhattacharya, Ana Burguete-García, Eduardo Castro-Nallar, Youping Deng, Christelle Desnues, et al. (+15)
167 [GO] 2021―Feb―21 The journey towards safely restarting faecal microbiota transplantation services in the UK during the COVID-19 era Mohammed Nabil Quraishi, Sahida Shabir, Susan E Manzoor, Christopher A Green, Naveen Sharma, Andrew D Beggs, Tariq H Iqbal
168 [GO] 2021―Feb―10 SARS-CoV-2 vaccines: fast track versus efficacy Dana Alkandari, Jenny A Herbert, Moustafa A Alkhalaf, Carol Yates, Stavros Panagiotou
169 [GO] 2021―Feb―06 COVID-19 cytokine storm syndrome: a threshold concept Luke Y C Chen, Tien T T Quach
170 [GO] 2021―Feb―06 Neutrophils as a pallbearer for SARS-CoV-2 disease burden - Authors’ reply René Lutter, Bernadette Schurink, Eva Roos, Lihui Guo, Paul van der Valk, Marianna Bugiani
171 [GO] 2021―Feb―05 Africa prepares for COVID-19 vaccines Paul Adepoju
172 [GO] 2021―Feb―05 Neutrophils as a pallbearer for SARS-CoV-2 disease burden David DW Twa, Christine D Lukac, Kevin Kuchinski, Aidan Nikiforuk, Inna Sekirov
173 [GO] 2021―Jan―27 Monitoring of human coronaviruses in Belgian primary care and hospitals, 2015-20: a surveillance study Natalie Fischer, Nicolas Dauby, Nathalie Bossuyt, Marijke Reynders, Michèle Gérard, Patrick Lacor, et al. (+12)
174 [GO] 2021―Jan―19 Insight into the practical performance of RT-PCR testing for SARS-CoV-2 using serological data: a cohort study Zhen Zhang, Qifang Bi, Shisong Fang, Lan Wei, Xin Wang, Jianfan He, et al. (+9)
175 [GO] 2020―Dec―21 Multiplex assays for the identification of serological signatures of SARS-CoV-2 infection: an antibody-based diagnostic and machine learning study Jason Rosado, Stéphane Pelleau, Charlotte Cockram, Sarah Hélène Merkling, Narimane Nekkab, Caroline Demeret, et al. (+13)
176 [GO] 2020―Dec―18 COVID-19 vaccines: the pandemic will not end overnight The Lancet Microbe
177 [GO] 2020―Dec―07 Mass testing for COVID-19 Talha Burki
178 [GO] 2020―Dec―07 How a microbe becomes a pandemic: a new story of the Black Death Monica H Green
179 [GO] 2020―Nov―20 SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis Muge Cevik, Matthew Tate, Ollie Lloyd, Alberto Enrico Maraolo, Jenna Schafers, Antonia Ho
180 [GO] 2020―Nov―05 Immunogenomic phases of COVID-19 and appropriate clinical management Ibrahim C Haznedaroglu
181 [GO] 2020―Nov―05 Innovative point-of-care molecular diagnostic test for COVID-19 in India Nivedita Gupta, Salaj Rana, Harpreet Singh
182 [GO] 2020―Nov―05 Changes in clinical laboratory operations and biosafety measures to mitigate biohazard risks during the COVID-19 pandemic Kay Weng Choy
183 [GO] 2020―Nov―05 COVID-19 response in central Asia Vijay Shankar Balakrishnan
184 [GO] 2020―Nov―05 Using genomics to improve preparedness and response of future epidemics or pandemics in Africa Chrispin Chaguza, Martin M Nyaga, Jason M Mwenda, Mathew D Esona, Khuzwayo C Jere
185 [GO] 2020―Nov―03 Co-infections: testing macrolides for added benefit in patients with COVID-19 Katharina Anna Sterenczak, Israel Barrantes, Thomas Stahnke, Oliver Stachs, Georg Fuellen, Nasrullah Undre
186 [GO] 2020―Oct―30 Innovation in wastewater near-source tracking for rapid identification of COVID-19 in schools Francis Hassard, Lian Lundy, Andrew C Singer, Jasmine Grimsley, Mariachiara Di Cesare
187 [GO] 2020―Oct―24 Dexamethasone and remdesivir: finding method in the COVID-19 madness Pauline Vetter, Laurent Kaiser, Alexandra Calmy, Thomas Agoritsas, Angela Huttner
188 [GO] 2020―Oct―07 NTDs in the time of COVID-19 Paul Adepoju
189 [GO] 2020―Oct―07 Cerebrospinal fluid findings in COVID-19 indicate autoimmunity Guglielmo Lucchese
190 [GO] 2020―Oct―07 COVID-19: we will not be returning to the old normal The Lancet Microbe
191 [GO] 2020―Sep―25 Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study Ania Wajnberg, Mayce Mansour, Emily Leven, Nicole M Bouvier, Gopi Patel, Adolfo Firpo-Betancourt, et al. (+13)
192 [GO] 2020―Sep―25 Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study Bernadette Schurink, Eva Roos, Teodora Radonic, Ellis Barbe, Catherine S C Bouman, Hans H de Boer, et al. (+24)
193 [GO] 2020―Sep―17 Assessing a novel, lab-free, point-of-care test for SARS-CoV-2 (CovidNudge): a diagnostic accuracy study Malick M Gibani, Christofer Toumazou, Mohammadreza Sohbati, Rashmita Sahoo, Maria Karvela, Tsz-Kin Hon, et al. (+27)
194 [GO] 2020―Sep―07 COVID-19 and fungal infection: the need for a strategic approach P Lewis White, Rishi Dhillon, Harriet Hughes, Matthew P Wise, Matthijs Backx
195 [GO] 2020―Sep―07 A locally sustainable approach to COVID-19 testing in Africa Elijah Songok
196 [GO] 2020―Sep―07 In preparation for a COVID-19-influenza double epidemic Vijay Shankar Balakrishnan
197 [GO] 2020―Aug―20 Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study Brian Hanley, Kikkeri N Naresh, Candice Roufosse, Andrew G Nicholson, Justin Weir, Graham S Cooke, et al. (+12)
198 [GO] 2020―Aug―18 Accelerating genomics-based surveillance for COVID-19 response in Africa Sofonias K Tessema, Seth C Inzaule, Alan Christoffels, Yenew Kebede, Tulio de Oliveira, Ahmed E Ogwell Ouma, et al. (+2)
199 [GO] 2020―Aug―06 Surveillance for COVID-19-associated pulmonary aspergillosis Li-An K Brown, Jayne Ellis, Rebecca Gorton, Surjo De, Neil Stone
200 [GO] 2020―Aug―06 Arboviruses and COVID-19: the need for a holistic view The Lancet Microbe
201 [GO] 2020―Aug―06 Cross-reactivity towards SARS-CoV-2: the potential role of low-pathogenic human coronaviruses Zhongren Ma, Pengfei Li, Yuepeng Ji, Aqsa Ikram, Qiuwei Pan
202 [GO] 2020―Aug―06 Stability of SARS-CoV-2 in different environmental conditions Reza Dehbandi, Mohammad Ali Zazouli
203 [GO] 2020―Aug―06 Stability of SARS-CoV-2 in different environmental conditions - Authors' reply Alex W H Chin, Leo L M Poon
204 [GO] 2020―Aug―06 Seroprevalence of SARS-CoV-2 in Hong Kong returnees William P Hanage, Victor I Vincent, Nicola M Low
205 [GO] 2020―Aug―06 Seroprevalence of SARS-CoV-2 in Hong Kong returnees - Authors' reply Kelvin Kai-Wang To, Kwok-Yung Yuen
206 [GO] 2020―Aug―06 Anosmia and hyposmia in health-care workers with undiagnosed SARS-CoV-2 infection Matt Lechner, Nicholas Counsell, Jacklyn Liu, Nicholas Eynon-Lewis, Santdeep Paun, Valerie J Lund, et al. (+2)
207 [GO] 2020―Jul―28 The challenges of informative wastewater sampling for SARS-CoV-2 must be met: lessons from polio eradication Kathleen M O'Reilly, David J Allen, Paul Fine, Humayun Asghar
208 [GO] 2020―Jul―16 Towards pandemic preparedness beyond COVID-19 Mahmoud M Naguib, Patrik Ellström, Josef D Järhult, Åke Lundkvist, Björn Olsen
209 [GO] 2020―Jul―07 SARS-CoV-2 in fruit bats, ferrets, pigs, and chickens: an experimental transmission study Kore Schlottau, Melanie Rissmann, Annika Graaf, Jacob Schön, Julia Sehl, Claudia Wylezich, et al. (+8)
210 [GO] 2020―Jul―03 The role of oral bacteria in COVID-19 Jay Patel, Victoria Sampson
211 [GO] 2020―Jul―03 COVID-19 and fungal superinfection Katie L Heard, Stephen Hughes, Nabeela Mughal, Luke S P Moore
212 [GO] 2020―Jul―03 COVID-19 testing in Africa: lessons learnt Pascale Ondoa, Yenew Kebede, Marguerite Massinga Loembe, Jinal N Bhiman, Sofonias Kifle Tessema, Abdourahmane Sow, et al. (+2)
213 [GO] 2020―Jul―03 Development of potential COVID-19 vaccines continues to accelerate Tony Kirby
214 [GO] 2020―Jul―03 COVID-19-associated pulmonary aspergillosis: adding insult to injury Giuseppe Bruno, Claudia Fabrizio, Giovanni Battista Buccoliero
215 [GO] 2020―Jul―03 COVID-19: a multifaceted threat to refugee camps Talha Burki
216 [GO] 2020―Jul―02 Anthroponotic risk of SARS-CoV-2, precautionary mitigation, and outbreak management Sarah J L Edwards, Joanne M Santini
217 [GO] 2020―Jun―18 Host range of SARS-CoV-2 and implications for public health Joanne M Santini, Sarah J L Edwards
218 [GO] 2020―Jun―11 Systematic SARS-CoV-2 screening in cerebrospinal fluid during the COVID-19 pandemic Grégory Destras, Antonin Bal, Vanessa Escuret, Florence Morfin, Bruno Lina, Laurence Josset
219 [GO] 2020―Jun―08 Low rate of bacterial co-infection in patients with COVID-19 Hugh Adler, Robert Ball, Michael Fisher, Kalani Mortimer, Madhur S Vardhan
220 [GO] 2020―Jun―08 COVID-19 and measles: double trouble for Burundi Sanjeet Bagcchi
221 [GO] 2020―Jun―08 COVID-19 diagnostics-not at the expense of other diseases Priya Venkatesan
222 [GO] 2020―Jun―08 Monitoring investments in coronavirus research and development Rebecca J Brown, Michael G Head
223 [GO] 2020―Jun―08 Optimising SARS-CoV-2 pooled testing for low-resource settings Farhan Majid, Saad B Omer, Asim Ijaz Khwaja
224 [GO] 2020―Jun―08 Stability and neutralising capacity of SARS-CoV-2-specific antibodies in convalescent plasma Torsten Tonn, Victor M Corman, Matthias Johnsen, Anja Richter, Roman N Rodionov, Christian Drosten, Stefan R Bornstein
225 [GO] 2020―Jun―03 Seroprevalence of SARS-CoV-2 in Hong Kong and in residents evacuated from Hubei province, China: a multicohort study Kelvin Kai-Wang To, Vincent Chi-Chung Cheng, Jian-Piao Cai, Kwok-Hung Chan, Lin-Lei Chen, Lok-Hin Wong, et al. (+16)
226 [GO] 2020―Jun―03 Population serology for SARS-CoV-2 is essential to regional and global preparedness Huaiyu Tian, Ottar N Bjornstad
227 [GO] 2020―Jun―02 An integrated national scale SARS-CoV-2 genomic surveillance network
228 [GO] 2020―May―11 Increasing accessibility in COVID-19 clinical trials Vijay Shankar Balakrishnan
229 [GO] 2020―May―11 Africa's struggle with inadequate COVID-19 testing Paul Adepoju
230 [GO] 2020―May―11 Solar ultraviolet radiation sensitivity of SARS-CoV-2 Ayse Seyer, Tamer Sanlidag
231 [GO] 2020―May―10 Diagnosing COVID-19-associated pulmonary aspergillosis Paul E Verweij, Jean-Pierre Gangneux, Matteo Bassetti, Roger J M Brüggemann, Oliver A Cornely, Philipp Koehler, et al. (+4)
232 [GO] 2020―Apr―24 Co-infections: potentially lethal and unexplored in COVID-19 Michael J Cox, Nicholas Loman, Debby Bogaert, Justin O'Grady
233 [GO] 2020―Apr―21 Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study Hin Chu, Jasper Fuk-Woo Chan, Terrence Tsz-Tai Yuen, Huiping Shuai, Shuofeng Yuan, Yixin Wang, et al. (+22)
234 [GO] 2020―Apr―21 SARS-CoV-2 cellular tropism Valeria Cagno
235 [GO] 2020―Apr―02 Stability of SARS-CoV-2 in different environmental conditions Alex W H Chin, Julie T S Chu, Mahen R A Perera, Kenrie P Y Hui, Hui-Ling Yen, Michael C W Chan, et al. (+2)
236 [GO] 2020―Apr―01 From PREDICT to prevention, one pandemic later Colin J Carlson

236 Results       Page 1


Last change 2023―Oct―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.043 sec